We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
+1.82%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$23.1M
Cap. Flow
+$26.6M
Cap. Flow %
20.15%
Top 10 Hldgs %
76.57%
Holding
38
New
12
Increased
12
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
OKUR
OnKure Therapeutics
OKUR
+$8.19M
2
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$3.38M
3
CNTB
Connect Biopharma Holdings
CNTB
+$2.45M
4
DSGN icon
Design Therapeutics
DSGN
+$2.36M
5
AVIR icon
Atea Pharmaceuticals
AVIR
+$2.01M

Top Sells

Rank Stock Value
1
PASG icon
Passage Bio
PASG
+$1.35M
2
RVP icon
Retractable Technologies
RVP
+$595K
3
LONA
LeonaBio Inc
LONA
+$443K
4
SRZN icon
Surrozen
SRZN
+$43.7K

Sector Composition

Rank Sector Weight
1 Healthcare 60.16%
2 Technology 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LSTA icon
26
Lisata Therapeutics
LSTA
$9.93M
$737K 0.56%
269,839
+26,000
+11% +$61.1K
ELVN icon
27
Enliven Therapeutics
ELVN
$3.78B
$692K 0.52%
50,000
– –
ACRS icon
28
Aclaris Therapeutics
ACRS
$715M
$686K 0.52%
+653,107
New +$1.99M
QQQ icon
29
PUT
Invesco QQQ Trust
QQQ
$436B
$661K 0.5%
300
+192
+178% +$72.9K
NGNE icon
30
Neurogene
NGNE
$672M
$478K 0.36%
24,666
– –
BBW icon
31
PUT
Build-A-Bear
BBW
$445M
$465K 0.35%
+1,500
New +$37.9K
QTTB icon
32
Q32 Bio
QTTB
$435M
$455K 0.34%
+41,562
New +$608K
CALC icon
33
CalciMedica
CALC
$11.7M
$416K 0.32%
145,424
+56,643
+64% +$164K
NXTC icon
34
NextCure
NXTC
$20.4M
$349K 0.26%
25,539
– –
TLIS
35
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$318K 0.24%
+42,743
New +$279K
PASG icon
36
Passage Bio
PASG
$14.5M
– –
-102,938
Closed -$1.35M
RVP icon
37
Retractable Technologies
RVP
$20.1M
– –
-499,959
Closed -$595K
SRZN icon
38
Surrozen
SRZN
$223M
– –
-5,951
Closed -$43.7K
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return
PMSA
Patrick M. Sweeney & Associates Libertyville, Illinois $156M AUM 19.16% 1-Year Est. Return
GSWA
Good Steward Wealth Advisors Clarksville, Tennessee $156M AUM 13.06% 1-Year Est. Return
SPM
Summit Portfolio Management Las Vegas, Nevada $155M AUM
MCA
McGuire Capital Advisors Bethany, Oklahoma $156M AUM

BML Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, BML Capital Management held 38 positions worth $132M, up 21% from $109M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

BML Capital Management deployed $26.6M of net new capital in Q4 2023, opening 12 new positions and adding to 12 existing holdings. Its largest new stake was OnKure Therapeutics: 131,423 shares worth $2.1M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was LeonaBio Inc, an estimated $443K trimmed.

  • BML Capital Management's largest Q4 2023 buy was OnKure Therapeutics: 131,423 shares worth $2.1M.
  • BML Capital Management added most to Atea Pharmaceuticals in Q4 2023, an estimated $2.01M increase.
  • BML Capital Management's biggest Q4 2023 reduction was LeonaBio Inc, cutting an estimated $443K.
  • BML Capital Management fully exited Passage Bio in Q4 2023, selling an estimated $1.35M.
  • BML Capital Management's ten largest holdings make up 77% of its $132M portfolio in Q4 2023.
  • BML Capital Management opened 12 new positions and closed 3 in Q4 2023.
  • BML Capital Management's portfolio value rose 21% quarter-over-quarter to $132M.

Based on BML Capital Management's 13F filing for Q4 2023, filed 30 Jan 2024.